Clinical Trial

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-02-06; most recent amendment 2026-04-21.
Status change: Not Yet Recruiting → Recruiting 2025-02-18
Trial Details
NCT Number NCT06816992
Lead Sponsor ORIC Pharmaceuticals
Collaborators: Janssen Research and Development LLC
Conditions Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
Enrollment 76 participants
Start Date 2025-02-27
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-24